Mesoblast (MESO) Retained Earnings (2014 - 2026)
Mesoblast (MESO) posted Retained Earnings of $106.3 million for Q4 2025, up 6.83% sequentially from $99.5 million in Q2 2025, and up 8.74% YoY from $97.8 million in Q4 2024.
Analysis
Mesoblast (MESO) Retained Earnings (2014 - 2026) Analysis & Trends
Mesoblast has reported Retained Earnings for 11 years, with the latest figure at $106.3 million in Q4 2025.
- Quarterly Retained Earnings rose 8.74% year-over-year to $106.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.3 million (up 8.74% YoY) and the FY2025 annual result came in at $99.5 million, up 110.95% from the prior year.
- Retained Earnings rose to $106.3 million in Q4 2025 per MESO's latest filing, from $99.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $106.3 million in Q4 2025 and troughed at -$908.8 million in Q2 2024.
- A 5-year average of $16.5 million and a median of $73.6 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 996.51% in 2024, then jumped 110.95% in 2025.
- Over 5 years, Retained Earnings stood at $68.1 million in 2021, then gained by 6.6% to $72.6 million in 2022, then climbed by 4.51% to $75.8 million in 2023, then climbed by 28.88% to $97.8 million in 2024, then gained by 8.74% to $106.3 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $106.3 million, $99.5 million, and $97.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | -1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07 Bn |
| Dec 31, 2025 | -1.05 Bn |
| Jun 30, 2025 | -1.01 Bn |
| Dec 31, 2024 | -956.70 Mn |
| Jun 30, 2024 | -908.76 Mn |
| Dec 31, 2023 | -853.34 Mn |
| Jun 30, 2023 | -820.81 Mn |
| Mar 31, 2023 | -798.89 Mn |
| Dec 31, 2022 | -780.29 Mn |
| Sep 30, 2022 | -755.80 Mn |
| Jun 30, 2022 | -738.92 Mn |
| Mar 31, 2022 | -717.46 Mn |
| Dec 31, 2021 | -696.16 Mn |
| Sep 30, 2021 | -670.21 Mn |
| Jun 30, 2021 | -647.57 Mn |
| Mar 31, 2021 | -625.51 Mn |
| Dec 31, 2020 | -598.99 Mn |
| Sep 30, 2020 | -573.30 Mn |
| Jun 30, 2020 | -548.76 Mn |
| Mar 31, 2020 | -516.15 Mn |